March Restructuring

[anonymous]

how do you know it’s august timeframe?

 

[anonymous]

Nothing against Ashfield reps. Just that they aren’t needed. It’s a huge waste of money and resources for BI when we are at a time that we are trying to be financially lean,
Let’s cut bait with the contract reps. It is time. And over lapping reps just never works well.

Maybe it’s the BI reps that should be looked at to be replaced. Just saying Ashfield is more economical. The HSBS and current management can handle territories

 

[anonymous]

Check out the Ashfield boards for New Customer Service Field Reps. These are for Spiriva. This is really not good. Cut the cost right in half.

 

[anonymous]

HSBS does not even know my customers. Really HSBS is not Not the answer here. In fact if they want to cut cost, Im certain they are getting paid more. Cut some of them too.

 

[anonymous]

Maybe it’s the BI reps that should be looked at to be replaced. Just saying Ashfield is more economical. The HSBS and current management can handle territories

The Ashfield rep you are working with now may cost more than a typical BI rep. Contract sales reps are not always the cheapest, however they are the more flexible and easiest to term/eliminate.

The Customer service reps being advertised by Ashfield are cheaper than a BI rep. Keep in mind this is also less money BI pays Ashfield.

Good luck to all

 

[anonymous]

how do you know it’s august timeframe?

I know because BI still needs us to drum up hype for Stiolto in Q2. After that’s out of the way, then the culling starts.

 

[anonymous]

I know because BI still needs us to drum up hype for Stiolto in Q2. After that’s out of the way, then the culling starts.

Not gonna lie, that sounds about right. After that, seems like a good time for some kind of mix up. Bi didn't learn and is paying the price. We have 3 disease states. Metabolic, Respiratory and Cardio. 2 of the 3 are going to be fairly worthless in a few years. Look at our pipeline. We have absolutely nothing coming out anytime soon. 3-4 years at the very least for anything other than expanded indications. But oh yeah, vision 2025. 20 Billion dollars in sales worldwide, by then. One TINY problem. You need products to sell. We won't have any. Thank god we didn't get a triple in COPD. That really saved us.

 

[anonymous]

Not gonna lie, that sounds about right. After that, seems like a good time for some kind of mix up. Bi didn't learn and is paying the price. We have 3 disease states. Metabolic, Respiratory and Cardio. 2 of the 3 are going to be fairly worthless in a few years. Look at our pipeline. We have absolutely nothing coming out anytime soon. 3-4 years at the very least for anything other than expanded indications. But oh yeah, vision 2025. 20 Billion dollars in sales worldwide, by then. One TINY problem. You need products to sell. We won't have any. Thank god we didn't get a triple in COPD. That really saved us.

Let's clarify "other than expanded indications". The Jardiance CV data for CHF is for real and that is a very large market. There are clinical trials going on presently across the country. To be fair Farxiga has similar data and is also doing clinical trials for CHF. Keep in mind that the CV marketplace is much,much bigger than diabetes. There are no guarantees but a CHF indication is very possible within 2 years. Will this be enough to offset Pradaxa and Spiriva going off patent? Probably not but one could see a CV/metabolic sales force in the future.

 

[anonymous]

Let's clarify "other than expanded indications". The Jardiance CV data for CHF is for real and that is a very large market. There are clinical trials going on presently across the country. To be fair Farxiga has similar data and is also doing clinical trials for CHF. Keep in mind that the CV marketplace is much,much bigger than diabetes. There are no guarantees but a CHF indication is very possible within 2 years. Will this be enough to offset Pradaxa and Spiriva going off patent? Probably not but one could see a CV/metabolic sales force in the future.

Without question all of that is true. But without question, there would still be a need for reduction in headcount. Can't have the entire company selling jardiance.

 

[anonymous]

Check out the Ashfield boards for New Customer Service Field Reps. These are for Spiriva. This is really not good. Cut the cost right in half.

The customer service reps are just that. They will go to offices that we (RBS) do not currently go to.

 

[anonymous]

Without question all of that is true. But without question, there would still be a need for reduction in headcount. Can't have the entire company selling jardiance.

Agree. The problem is if they throw all reps into big pool and do cuts based on ranking, where you live etc. That's what happened a few years ago in respiratory but in that scenario specialty reps bounced PCP.

 

[anonymous]

The customer service reps are just that. They will go to offices that we (RBS) do not currently go to.

I think the CSRs will be paid by BI to do more than call on low volume, no-see offices that current reps don’t call on.

 

[anonymous]

Hot off the press: Hand over your Humira biosim launch plans, judge tells Boehringer in AbbVie patent fight

This would create a LOT of sales jobs. Humira is 6 Billion $ drug. All depends on the judge now...

 

[anonymous]

Agree. The problem is if they throw all reps into big pool and do cuts based on ranking, where you live etc. That's what happened a few years ago in respiratory but in that scenario specialty reps bounced PCP.

....as they (we) should have.

 

[anonymous]

Hot off the press: Hand over your Humira biosim launch plans, judge tells Boehringer in AbbVie patent fight

This would create a LOT of sales jobs. Humira is 6 Billion $ drug. All depends on the judge now...

Why are you yelling at us???

 

[anonymous]

Ha BI couldn’t sell a biologic / bio similar! Not saying the sales people aren’t competent just any real leadership left in large molecule BIPi Pharma has left the building.
This company can ruin a wet dream!
They lucked into profits back in the day and their luck has run out

 

[anonymous]

Hmmm..... No change to Q2 PLANiT? Future’s so bright I gotta wear shades.

 

[anonymous]

Hmmm..... No change to Q2 PLANiT? Future’s so bright I gotta wear shades.

No big deal. Just weighting’s will stay exactly the same. Just focus on the pull through initiative

 

[anonymous]

Pull through?
Better pull out before you get hit with child support

 

[anonymous]

Hmmm..... No change to Q2 PLANiT? Future’s so bright I gotta wear shades.

No change to Q2 PLANiT but PLANiT will be open end of Q2 for Q3. Like I said before, the bloodbath for 2019 will be in 2H 2019.